Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of 177 LuPSMA-617 vs Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease

NCT04663997 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.

NCT NCT04663997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04663997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of 177 LuPSMA-617 vs Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease
Lead sponsor
Canadian Cancer Trials Group
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 11, 2021
Completion date
December 31, 2026
Enrollment
200 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer